We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Athenex Inc | NASDAQ:ATNX | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.2031 | 0.2032 | 0.2033 | 0 | 01:00:00 |
Athenex will introduce its new brand established for the oncology platform, Athenex Oncology, at its exhibition booth (#4150) at ASCO 2019 (exhibition dates: June 1 to 3, 2019), which will also showcase the potential of the Orascovery Platform and latest development pipeline.
Athenex has four abstracts accepted for poster presentation and two abstracts accepted for online publication only.
Details of Poster Presentations:
Title: (Abstract TPS1116) KX-ORAX-001: An open label, randomized, multicenter, Phase III registrational study to determine the safety, tolerability, and tumor response of Oraxol (HM30181A + oral paclitaxel) and its comparability to IV paclitaxel in patients with metastatic breast cancer (MBC). Presenter: Gerardo Antonio Umanzor Funez, DEMEDICA, San Pedro Sula, HondurasPoster Session: Breast Cancer—Metastatic Session Date, Time, Location: Sunday, June 2, 2019, 8:00 AM-11:00 AM Central Daylight Time, Hall AThe abstract is available on the ASCO website here.
Title: (Abstract 1084) Oral paclitaxel in the treatment of metastatic breast cancer (MBC) patients. Presenter: Ming-Shen Dai, Tri-Service General Hospital, Taipei, Taiwan Poster Session: Breast Cancer—Metastatic Session Date, Time, Location: Sunday, June 2, 2019, 8:00 AM-11:00 AM Central Daylight Time, Hall AThe abstract is available on the ASCO website here.
Title: (Abstract 3032) A Phase 1 study of the oral administration of irinotecan in combination with the potent P-glycoprotein (P-gp) inhibitor HM30181A. Presenter: Antonio Jimeno, University of Colorado, Aurora, CO Poster Session: Developmental Therapeutics and Tumor Biology (Nonimmuno) Session Date, Time, Location: Saturday, June 1, 2019, 8:00 AM-11:00 AM Central Daylight Time, Hall AThe abstract is available on the ASCO website here.
Title: (Abstract 3090) Design, engineering, and characterization of a novel long-acting (Pegylated) single isomer human arginase for arginine depriving anti-cancer treatment. Presenter: Kuo-Ming Yu, Athenex, Inc., Buffalo, NYPoster Session: Developmental Therapeutics and Tumor Biology (Nonimmuno) Session Date, Time, Location: Saturday, June 1, 2019, 8:00 AM-11:00 AM Central Daylight Time, Hall AThe abstract is available on the ASCO website here.
Abstracts Accepted for Online Publication Only:
Title: (Abstract e15518) A phase Ib study of oraxol in combination with ramucirumab in patients with gastric or esophageal cancers who failed previous chemotherapy.The abstract is available on the ASCO website here.
Title: (Abstract e12577) Eribulin ORA: A novel oral formulation of eribulin based on combination withthe P-gp inhibitor HM30181A.The abstract is available on the ASCO website here.
The Orascovery platform was initially developed by Hanmi Pharmaceuticals and licensed exclusively to Athenex for all major worldwide territories except Korea, which is retained by Hanmi.
About Athenex, Inc. Founded in 2003, Athenex, Inc. is a global clinical stage biopharmaceutical company dedicated to becoming a leader in the discovery, development and commercialization of next generation drugs for the treatment of cancer. Athenex is organized around three platforms, including an Oncology Innovation Platform, a Commercial Platform and a Global Supply Chain Platform. The Company’s current clinical pipeline is derived from four different platform technologies: (1) Orascovery, based on non-absorbed P-glycoprotein inhibitor, (2) Src kinase inhibition, (3) T-cell receptor-engineered T-cells (TCR-T), and (4) Arginine deprivation therapy. Athenex’s employees worldwide are dedicated to improving the lives of cancer patients by creating more active and tolerable treatments. Athenex has offices in Buffalo and Clarence, New York; Cranford, New Jersey; Houston, Texas; Chicago, Illinois; Hong Kong; Taipei, Taiwan; and multiple locations in Chongqing, China. For more information, please visit www.athenex.com.
Forward-Looking Statements Except for historical information, all of the statements, expectations, and assumptions contained in this press release are forward-looking statements. These forward-looking statements are typically identified by terms such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “foresee,” “guidance,” “intend,” “likely,” “may,” “plan,” “potential,” “predict,” “preliminary,” “probable,” “project,” “promising,” “seek,” “should,” “will,” “would,” and similar expressions. Actual results might differ materially from those explicit or implicit in the forward-looking statements. Important factors that could cause actual results to differ materially include: the development stage of our primary clinical candidates and related risks involved in drug development, clinical trials, regulation, manufacturing and commercialization; our reliance on third parties for success in certain areas of Athenex’s business; our history of operating losses and need to raise additional capital to continue as a going concern; competition; intellectual property risks; risks relating to doing business in China; and the other risk factors set forth from time to time in our SEC filings, copies of which are available for free in the Investor Relations section of our website at http://ir.athenex.com/phoenix.zhtml?c=254495&p=irol-sec or upon request from our Investor Relations Department. All information provided in this release is as of the date hereof and we assume no obligation and do not intend to update these forward-looking statements, except as required by law.
CONTACTS
Investor Relations:
Tim McCarthy Managing Director, LifeSci Advisors, LLC Tel: +1 716-427-2952 Direct: +1 212-915-2564
Athenex, Inc.:
Randoll Sze Chief Financial Officer Email: randollsze@athenex.com
Jacqueline Li Corporate Development and Investor Relations Email: jacquelineli@athenex.com
1 Year Athenex Chart |
1 Month Athenex Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions